Our products include the Tiara™ technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer™ for the treatment of refractory angina.
A Canadian biotech company, headquartered in Vancouver, B.C. Canada, we are a publicly traded company, listed on NASDAQ: (NVCN) and the Toronto Stock Exchange TSX: (NVCN)
We invite you to register to receive Neovasc news updates by email.